INOVIO to Report First Quarter 2025 Financial Results on May 13, 2025
INOVIO (NASDAQ: INO), a biotechnology company specializing in DNA medicines, has scheduled its first quarter 2025 financial results announcement for May 13, 2025, after market close.
The company, which focuses on developing treatments for HPV-associated diseases, cancers, and infectious diseases, will host a live conference call and webcast at 4:30 p.m. ET on the same day. The event will include:
- A general business update presentation
- Live Q&A session with analysts
- Webcast access through http://ir.inovio.com/events-and-presentations/default.aspx
The webcast will be available for replay for 90 days following the event. This listen-only event provides investors and stakeholders an opportunity to stay updated on INOVIO's financial performance and business developments.
INOVIO (NASDAQ: INO), un'azienda biotecnologica specializzata in medicinali a base di DNA, ha programmato l'annuncio dei risultati finanziari del primo trimestre 2025 per il 13 maggio 2025, dopo la chiusura dei mercati.
L'azienda, che si concentra sullo sviluppo di trattamenti per malattie associate a HPV, tumori e malattie infettive, terrà una teleconferenza e una diretta web alle 16:30 ET dello stesso giorno. L'evento includerà:
- Una presentazione generale sull'andamento aziendale
- Una sessione di domande e risposte dal vivo con gli analisti
- Accesso alla diretta web tramite http://ir.inovio.com/events-and-presentations/default.aspx
La diretta sarà disponibile in replica per 90 giorni dopo l'evento. Questo evento in sola ascolto offre a investitori e stakeholder l'opportunità di rimanere aggiornati sulle performance finanziarie e sugli sviluppi aziendali di INOVIO.
INOVIO (NASDAQ: INO), una compañía biotecnológica especializada en medicamentos de ADN, ha programado el anuncio de sus resultados financieros del primer trimestre de 2025 para el 13 de mayo de 2025, después del cierre del mercado.
La empresa, que se enfoca en desarrollar tratamientos para enfermedades asociadas al VPH, cánceres y enfermedades infecciosas, realizará una llamada en conferencia en vivo y una transmisión web a las 4:30 p.m. ET del mismo día. El evento incluirá:
- Una presentación general sobre el estado del negocio
- Una sesión de preguntas y respuestas en vivo con analistas
- Acceso a la transmisión web a través de http://ir.inovio.com/events-and-presentations/default.aspx
La transmisión estará disponible para repetición durante 90 días después del evento. Este evento solo para escucha brinda a inversores y partes interesadas la oportunidad de mantenerse informados sobre el desempeño financiero y los desarrollos comerciales de INOVIO.
INOVIO (NASDAQ: INO)는 DNA 의약품을 전문으로 하는 생명공학 기업으로, 2025년 1분기 재무 실적 발표를 2025년 5월 13일 시장 마감 후에 예정하고 있습니다.
HPV 관련 질환, 암 및 감염병 치료제 개발에 집중하는 이 회사는 같은 날 오후 4시 30분(동부시간)에 라이브 컨퍼런스 콜과 웹캐스트를 개최할 예정입니다. 이벤트 내용은 다음과 같습니다:
- 전반적인 사업 현황 발표
- 애널리스트와의 실시간 질의응답 세션
- 웹캐스트 접속: http://ir.inovio.com/events-and-presentations/default.aspx
웹캐스트는 행사 후 90일간 다시보기로 제공됩니다. 이 청취 전용 이벤트는 투자자와 이해관계자에게 INOVIO의 재무 성과와 사업 진행 상황을 최신으로 확인할 기회를 제공합니다.
INOVIO (NASDAQ : INO), une entreprise de biotechnologie spécialisée dans les médicaments à base d'ADN, a programmé l'annonce de ses résultats financiers du premier trimestre 2025 pour le 13 mai 2025, après la clôture des marchés.
L'entreprise, qui se concentre sur le développement de traitements pour les maladies associées au HPV, les cancers et les maladies infectieuses, organisera une conférence téléphonique en direct et une diffusion web à 16h30 (heure de l'Est) le même jour. L'événement comprendra :
- Une présentation générale de l'activité
- Une session de questions-réponses en direct avec les analystes
- Accès à la diffusion web via http://ir.inovio.com/events-and-presentations/default.aspx
La diffusion sera disponible en replay pendant 90 jours après l'événement. Cet événement en mode écoute seule offre aux investisseurs et parties prenantes l'opportunité de rester informés sur la performance financière et les développements commerciaux d'INOVIO.
INOVIO (NASDAQ: INO), ein Biotechnologieunternehmen, das sich auf DNA-Medikamente spezialisiert hat, hat die Bekanntgabe der Finanzergebnisse für das erste Quartal 2025 für den 13. Mai 2025 nach Börsenschluss angekündigt.
Das Unternehmen, das sich auf die Entwicklung von Behandlungen für HPV-assoziierte Krankheiten, Krebserkrankungen und Infektionskrankheiten konzentriert, wird am selben Tag um 16:30 Uhr ET eine Live-Konferenzschaltung und Webcast veranstalten. Die Veranstaltung umfasst:
- Eine allgemeine Unternehmensaktualisierung
- Eine Live-Fragerunde mit Analysten
- Zugang zum Webcast über http://ir.inovio.com/events-and-presentations/default.aspx
Der Webcast wird 90 Tage nach der Veranstaltung als Wiederholung verfügbar sein. Diese nur zum Zuhören angebotene Veranstaltung bietet Investoren und Interessenten die Möglichkeit, über die finanzielle Entwicklung und Geschäftsfortschritte von INOVIO informiert zu bleiben.
- DNA medicines portfolio focused on high-value areas: HPV diseases, cancers, and infectious diseases
- None.
The live webcast will be available online at http://ir.inovio.com/events-and-presentations/default.aspx. This is a listen-only event but will include a live Q&A with analysts. The webcast will be archived and available for replay for 90 days following the event.
About INOVIO
INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancers, and infectious diseases. INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools. For more information, visit www.inovio.com.
Contacts
Media: Jennie Willson, (267) 429-8567, communications@inovio.com
Investors: Peter Vozzo - ICR Healthcare, (443) 213-0505, investor.relations@inovio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/inovio-to-report-first-quarter-2025-financial-results-on-may-13-2025-302440001.html
SOURCE INOVIO Pharmaceuticals, Inc.
FAQ
When will INOVIO (INO) release Q1 2025 earnings?
How can I listen to INOVIO's Q1 2025 earnings call?
How long will INOVIO's Q1 2025 earnings webcast be available for replay?
What diseases does INOVIO (INO) focus on treating?
Will analysts be able to ask questions during INOVIO's Q1 2025 earnings call?
